Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Pharmacologic Effect of CP-690,550 in Patients With Psoriasis  by Boy, Mary G. et al.
toxicity, as demonstrated by healthy
regenerated hairs post-grafting.
Animals were handled according to
the guidelines of Institutional Animal
Care and Use Committee at Cincinnati
Children’s Hospital.
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TO THE EDITOR
Aberrant activation of the cellular im-
mune system is recognized as the
driving pathogenic event of psoriasis
(Krueger and Bowcock 2005), con-
firmed by an infiltration of T-cells into
psoriatic lesions (Gudjonsson et al
2004). Inhibition of Janus kinase 3
(JAK3) in T cells is expected to un-
couple early T-cell receptor-triggered
signaling from downstream events
(Pesu et al 2005) and, for this reason,
JAK3 inhibitors could be effective in
T-cell-mediated disorders such as psori-
asis. CP-690,550 is an orally active
highly selective JAK inhibitor and
Abbreviations: AE, adverse events; b.i.d., two times-daily dosing; IL, interleukin; JAK, Janus kinase; K16,
keratin 16; LSM, least squares mean; PGA, Physician’s Global Assessment (of Psoriasis); PLSS, Psoriatic
Lesion Severity Sum; q.d., once-daily dosing; SD, standard deviation; SE, standard error
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potent inhibitor of JAK3, being deve-
loped as an immunosuppressive treat-
ment for autoimmune diseases and for
the prevention of allograft rejection
(Changelian et al 2003). Repeat doses
of CP-690,550 were studied in medically
stable patients with psoriasis; the results
suggest the potential for effectiveness of
JAK3-mediated immunosuppression in
this T-cell-mediated condition.
In this phase 1, randomized, dose
escalation, double-blind study, each of
the six CP-690,550 dosage cohorts (oral
administration of 5, 10, 20, 30, and
50 mg two times-daily (b.i.d.) and
60 mg once-daily (q.d.)) had a concur-
rent, parallel, placebo control. Cohorts
were conducted sequentially except
for the 60 mg q.d. and 50 mg b.i.d.
cohorts, which were conducted
concurrently. Patients received treat-
ment for 14 days and follow-up assess-
ments were conducted 4, 7, 14, and
28 days after the last dose and until
any clinically relevant abnormalities
relating to the study were resolved.
Biopsies were conducted at baseline
and at day 14. Institutional Review
Board approval was obtained from
the Human Volunteers Research
Committee at Arkansas Research,
and written informed consent was
obtained from each patient. The
Declaration of Helsinki protocols were
followed.
A total of 59 Caucasian patients
(aged 23–63 years) with at least one
evaluable plaque of psoriasis were
enrolled in the placebo (n¼13) or the
CP-690,550 groups: five each at 5 mg
b.i.d. and 10 mg b.i.d., 10 at 20 mg
b.i.d., nine each at 30 mg b.i.d. and
60 mg q.d., and eight at 50 mg b.i.d.
(CONSORT details for each cohort are
provided in Figure S1). Index psoriasis
lesions were assessed for erythema,
induration, and scaling using a Psoriatic
Lesion Severity Sum (PLSS) score; a
total score of 5–12 and an induration
score of 2–4 were required at baseline.
Results showed a dose-dependent
decrease (improvement) in the least
squares mean (LSM) of percentage
change in PLSS score from baseline to
day 14 for all CP-690,550 doses except
5 mg b.i.d. (Po0.01 vs placebo)
(Figure 1). Three out of eight patients
in the highest dose group (50 mg b.i.d.)
reduced their PLSS scores to 0 (from
baseline scores of 4–6) on day 14. These
results were also reflected in an analysis
of the change from baseline in PLSS
component scores (erythema, indura-
tion, and scaling) (data not shown).
Physician’s Global Assessment
(PGA) scores for the index lesions at
baseline were similar across the groups
(mean±SD values 2.8±0.8–4.0±0.9,
indicating moderate or mild-to-moder-
ate disease). The LSM increase (signi-
fying improvement) from baseline to
day 14 in PGA scores was significantly
greater (Po0.01) in the CP-690,550 30
and 50 mg b.i.d. groups than in the
placebo group. The percentage of
patients with a day 14 PGA response
(defined as ‘almost clear’ or ‘clear’ and
X2-point PGA score improvement
from baseline) was significantly higher
(Po0.05) in the CP-690,550 50 mg
b.i.d. group than in the placebo group.
A total of six patients receiving
CP-690,550 (5 mg b.i.d., n¼1; 20 mg
b.i.d., n¼1; 30 mg b.i.d., n¼ 4) and
two patients receiving placebo had
evaluable biopsies at day 14. When
compared with baseline biopsies, a
marked histological improvement (to
normal or near normal) was seen in
three of the biopsied patients receiving
CP-690,550, all at the higher dose of
30 mg b.i.d. A clear histological im-
provement was observed in one of the
biopsied patients receiving placebo.
The remaining biopsied patients
showed minimal or no changes com-
pared with baseline. Examples of im-
munohistochemistry of biopsies from
patients who received placebo or
CP-690,550 30 mg b.i.d. are shown in
Figure 2.
In all patients with biopsies, baseline
keratin 16 (K16, a keratinocyte growth-
activation marker) expression was nor-
mal (score of 0 on the 5-point (0–4)
scale) or near normal (score of 1) in the
nonlesional biopsy but highly abnormal
(score of 4) in the lesional biopsy. At
day 14, lesional biopsy K16 expression
had improved to normal or near normal
in three of the four patients in the 30 mg
b.i.d. group (including the patient
shown in Figure 2), had improved (to
a score of 2) in 1 of the 2 placebo
recipients, and remained unchanged in
the four other patients who underwent
skin biopsy. Improvement in
the 30 mg b.i.d. group was also evi-
denced by a day 14 decrease from
baseline in mean±SD lesion thickness
(157±165 microns) and in the num-
ber of cells positive for tested biomar-
kers per linear millimeter of lesion
biopsy: CD3þ (40±103 epidermal,
35±94 dermal), CD8þ (57±20
epidermal, 33±91 dermal), CD11cþ
(64±63 epidermal, 181±189 der-
mal), CD25þ (36±24 epidermal,
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Figure 1. Change in PLSS score from baseline to day 14. Change in PLSS score from baseline (screening)
to day 14 (the last dosing day) in medically stable patients with psoriasis administered CP-690,550 or
placebo. The PLSS scores of a representative lesion at baseline (screening) were similar across all groups
(mean±SD 5.3±1.0–6.4±1.5). b.i.d., two times-daily; LSM %, least squares mean of % change; PLSS
score, Psoriatic Lesion Severity Sum score; NA, not applicable; q.d., once-daily; SE, standard error.
*2-sided nominal P-value comparing CP-690,550 versus placebo.
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45±55 dermal), and CD83þ
(16±11 epidermal, 15±9 dermal).
There were 16 adverse events (AEs)
in 10 patients, most commonly head-
ache (n¼5) and nausea (n¼ 3); all but
three occurred in patients receiving
CP-690,550. All were mild except for
moderate worsening psoriasis (n¼ 1).
There was one serious AE, mild atrial
fibrillation (10 mg b.i.d. group), which
was not considered treatment-related.
Overall, there was no evidence of
dose–response in AE occurrence, and
no dose-related or clinically significant
changes in vital signs or electrocardio-
grams. Total cholesterol in the 30 and
50 mg b.i.d. groups, low-density lipo-
protein cholesterol in the 30 mg b.i.d.
group, and triglycerides in the 50 mg
b.i.d. group were elevated relative to
placebo. Other abnormal safety labora-
tory tests showed no clear relationship
to CP-690,550 dose.
These findings demonstrate that
JAK3 inhibition may provide a viable
mechanism of action for the treatment
of psoriasis, and to our knowledge this
is previously unreported. Through in-
hibition of JAK3, CP-690,550 is thought
to suppress the intracellular signal
transduction from the common g chain
receptors for the cytokines IL-2, IL-4,
IL-7, IL-9, IL-15, and IL-21 (Borie et al
2004), thereby disrupting the activa-
tion, proliferation, and homeostasis of
helper and cytotoxic T lymphocytes.
The inhibition of IL-15 activity may
be of particular relevance because
IL-15 shows high levels of expression
Patient 1 (elbow): CP-690,550 30 mg two times-daily Patient 3 (knee): placebo
Baseline (screening)
H&E CD3 K16
CD14CD11cCD8
CD25 CD40 CD83
H&E CD3 K16
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CD25 CD40 CD83
H&E CD3 K16
CD14CD11cCD8
CD25 CD40 CD83
H&E CD3 K16
CD14CD11cCD8
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Normal skin
Day 14Day 14
CD3 K16
CD14CD11cCD8
CD25 CD40 CD83
Baseline (screening)
Figure 2. Immunohistochemistry of biopsies from baseline to day 14. Stains (immunohistochemistry) of biopsies pretreatment and posttreatment of patient 1,
who received CP-690,550 30 mg b.i.d. and patient 3, who received placebo. Bottom biopsy is of the psoriasis-free skin of patient 1, shown for comparison. Scale
bar¼ 400 mm. H&E, hematoxylin and eosin; K16, keratin 16; b.i.d., two times-daily.
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and enhanced binding activity in
psoriasis lesions, and is also associated
with increases in the apoptotic resis-
tance of keratinocytes (Ruckert et al
2000). The sample size of this study
was relatively small, no adjustments
were made for multiple comparisons
due to the exploratory nature of the
analyses, and placebo patients across
the six cohorts were combined into a
single group for all analyses. Despite
these limitations, this study demon-
strated substantial improvement in
psoriatic lesion severity suggesting
that CP-690,550 is a potent immuno-
suppressant. Further studies with
CP-690,550 in immune-mediated dis-
orders are warranted.
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SUPPLEMENTARY MATERIAL
Figure S1. CONSORT details. Patient flow for
each cohort throughout the study.
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TO THE EDITOR
Transmembrane collagen XVII is a
hemidesmosomal component that is
essential for the anchorage of epithelial
cells to the basement membrane
(Franzke et al., 2005). Mutations in
the collagen XVII gene, COL17A1, are
associated with junctional epidermoly-
sis bullosa. The majority of COL17A1
mutations lead to a premature termina-
tion codon and the absence of collagen
XVII in the skin, whereas missense
mutations or deletions of amino acids
are less common (Aumailley et al.,
2006; Varki et al., 2006). Analogously
to other collagens, the glycine
substitutions located in the largest
collagenous domain of collagen XVII,
Col15, interrupt the triple-helix forma-
tion and lead to partial unfolding of the
ectodomain (Va¨isa¨nen et al., 2005).
However, it is possible that glycine
substitutions also interfere with the
transport of collagen XVII within the
secretory pathway and its post-transla-
tional modifications and membrane
targeting.
Here we have analyzed the subcel-
lular localization of collagen XVII with
glycine substitutions G539E, G609D,
G612R, G627V, and G633D, and the
in-frame deletion of amino acids
779–787 (D779–787) expressed transi-
ently in COS-7 cells (McGrath et al.,
1996; Chavanas et al., 1997; Floeth
et al., 1998; Tasanen et al., 2000;
Va¨isa¨nen et al., 2005). Wild-type col-
lagen XVII was localized in the cell
plasma membrane in immunofluores-Abbreviations: ER, endoplasmic reticulum
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